Wells Fargo Initiates Coverage On Celldex Therapeutics with Underweight Rating, Announces Price Target of $21
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Derek Archila has initiated coverage on Celldex Therapeutics (NASDAQ:CLDX) with an Underweight rating and a price target of $21.
August 22, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Celldex Therapeutics has been given an Underweight rating by Wells Fargo with a price target of $21.
The Underweight rating from Wells Fargo suggests that the analyst believes Celldex Therapeutics' stock is expected to underperform compared to other stocks. This could potentially lead to a decrease in the stock's price in the short term. The price target of $21 provides a benchmark for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100